مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

253
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

113
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

COTREATMENT WITH FUROSEMIDE AND HYPERTONIC SALINE DECREASES SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND SERUM CREATININE CONCENTRATIONS IN TRAUMATIC BRAIN INJURY: A RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL

Pages

  1130-1140

Abstract

 Acute kidney injury (AKI) occurs both after TRAUMATIC BRAIN INJURY (TBI) and after HYPERTONIC SALINE administration; FUROSEMIDE may be useful in preventing AKI indirectly. Serum NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (sNGAL) is superior to SERUM CREATININE (sCr) in diagnosing early AKI. We compared the administration of HYPERTONIC SALINE plus FUROSEMIDE (HTS+F) versus HYPERTONIC SALINE (HTS), using sCr and sNGAL to investigate kidney injury in patients with TBI. This randomized, single-blind clinical trial was conducted from August 2016 to July 2017 in a neurosurgical intensive care unit, and included patients with a Glasgow Coma Score (GCS) 7-13 and brain edema. One group (n=22) received HYPERTONIC SALINE 5% (100 mL over 60 min then 20 mL/h) plus FUROSEMIDE (40 mg over 60 min then 0.05 mg/kg per hour) for 72 h. The other group (n=21) received only HYPERTONIC SALINE 5%, in the same dose as noted above. The sCr and sNGAL concentrations, GCS, and length of stay were measured. Mean ± SD differences were -51.15 (47.07) and 9.96 (64.23) ng/mL for sNGAL and -0.12 (0.22) and -0.005 (0.2) mg/dL for sCr in HTS+F group and HTS group respectively (both p<0.001). The incidence of stage one AKI according to Improving Global Outcomes (KDIGO) criteria was 4.5% in the HTS+F group and 19.0% in the HTS group (p=0.16). Hypokalemia was common in both groups.HTS+F group, compared with HTS group, was associated with lower concentrations of sCr and sNGAL. Incidence AKI (KDIGO criteria) did not have difference between groups.

Cites

  • No record.
  • References

  • No record.
  • Cite

    APA: Copy

    JAFARI, MARZIYEH, ALA, SHAHRAM, HADDADI, KAVEH, ALIPOUR, ABBAS, MOJTAHEDZADEH, MOJTABA, EHTESHAMI, SAEID, ABEDIANKENARI, SAEID, SHAFIZAD, MISAGH, SALEHIFAR, EBRAHIM, & KHALILI, FOROOGH. (2018). COTREATMENT WITH FUROSEMIDE AND HYPERTONIC SALINE DECREASES SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND SERUM CREATININE CONCENTRATIONS IN TRAUMATIC BRAIN INJURY: A RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 17(3), 1130-1140. SID. https://sid.ir/paper/288759/en

    Vancouver: Copy

    JAFARI MARZIYEH, ALA SHAHRAM, HADDADI KAVEH, ALIPOUR ABBAS, MOJTAHEDZADEH MOJTABA, EHTESHAMI SAEID, ABEDIANKENARI SAEID, SHAFIZAD MISAGH, SALEHIFAR EBRAHIM, KHALILI FOROOGH. COTREATMENT WITH FUROSEMIDE AND HYPERTONIC SALINE DECREASES SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND SERUM CREATININE CONCENTRATIONS IN TRAUMATIC BRAIN INJURY: A RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2018;17(3):1130-1140. Available from: https://sid.ir/paper/288759/en

    IEEE: Copy

    MARZIYEH JAFARI, SHAHRAM ALA, KAVEH HADDADI, ABBAS ALIPOUR, MOJTABA MOJTAHEDZADEH, SAEID EHTESHAMI, SAEID ABEDIANKENARI, MISAGH SHAFIZAD, EBRAHIM SALEHIFAR, and FOROOGH KHALILI, “COTREATMENT WITH FUROSEMIDE AND HYPERTONIC SALINE DECREASES SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND SERUM CREATININE CONCENTRATIONS IN TRAUMATIC BRAIN INJURY: A RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 17, no. 3, pp. 1130–1140, 2018, [Online]. Available: https://sid.ir/paper/288759/en

    Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button